A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

NCT05460273 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Triple Negative Breast Cancer

Interventions

DRUG: Datopotamab Deruxtecan (Dato-DXd)

Sponsor

AstraZeneca

Collaborators

[object Object]